Published in J Am Soc Nephrol on June 10, 2010
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.95
Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One (2015) 1.46
Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension (2010) 1.05
Diabetic angiopathy and angiogenic defects. Fibrogenesis Tissue Repair (2012) 0.96
Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol (2012) 0.93
Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol (2011) 0.90
Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One (2012) 0.89
Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol (2015) 0.88
VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice. Am J Physiol Renal Physiol (2012) 0.87
Podocyte-Specific Deletion of Yes-Associated Protein Causes FSGS and Progressive Renal Failure. J Am Soc Nephrol (2015) 0.85
Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature. Pediatr Nephrol (2013) 0.84
Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS One (2014) 0.83
Bevacizumab for glioblastoma. Ther Clin Risk Manag (2015) 0.81
Anti-angiogenic therapy in high-grade glioma (treatment and toxicity). Curr Treat Options Neurol (2013) 0.81
Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma. Cancer Cell Int (2014) 0.81
Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist (2015) 0.80
Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis. PLoS One (2014) 0.79
Development of nephrotic syndrome after administration of sorafenib in a case of metastatic renal cell carcinoma. Case Rep Med (2011) 0.79
Proteins from Avastin® (bevacizumab) show tyrosine nitrations for which the consequences are completely unclear. PLoS One (2012) 0.79
Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. Case Rep Oncol (2012) 0.78
Emergency open incarcerated hernia repair with a biological mesh in a patient with colorectal liver metastasis receiving chemotherapy and bevacizumab uncomplicated wound healing. Case Rep Emerg Med (2014) 0.77
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. Br J Cancer (2016) 0.76
Efficacy and safety of bevacizumab for the treatment of glioblastoma. Exp Ther Med (2015) 0.76
Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature. BMC Res Notes (2013) 0.75
Renal sclerosing peritubular nodule-how rare is it? Clin Kidney J (2013) 0.75
Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther (2016) 0.75
Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Therap Adv Gastroenterol (2013) 0.75
Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review. Onco Targets Ther (2016) 0.75
Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration. J Nephropathol (2017) 0.75
Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome. Pediatr Nephrol (2016) 0.75
Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol (2008) 15.17
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 9.77
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol (2009) 7.80
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (2008) 6.23
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008) 5.04
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol (2005) 4.32
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis (2007) 3.47
Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med (1983) 3.32
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res (2005) 3.00
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol (2009) 2.97
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol (2007) 2.93
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int (2004) 2.42
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol (2009) 2.34
Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol (2007) 1.86
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant (2008) 1.76
Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol (2007) 1.63
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst (2008) 1.63
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer (2009) 1.45
Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol (2001) 1.12
Selecting and appraising studies for a systematic review. Ann Intern Med (1997) 1.11
Glomerular disease related to anti-VEGF therapy. Kidney Int (2008) 1.03
Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol (2006) 1.02
Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. Clin Exp Nephrol (2009) 0.91
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA (2008) 7.13
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol (2008) 2.63
Class prediction models of thrombocytosis using genetic biomarkers. Blood (2009) 1.92
Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factor-stimulated epithelial morphogenesis. Mol Cell (2003) 1.83
Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens (2010) 1.50
Nonnatural protein-protein interaction-pair design by key residues grafting. Proc Natl Acad Sci U S A (2007) 1.30
Community-wide evaluation of methods for predicting the effect of mutations on protein-protein interactions. Proteins (2013) 1.20
Case 7-2006: a man with altered mental status and acute renal failure. N Engl J Med (2006) 1.09
Histone deacetylase inhibition activates transcription factor Nrf2 and protects against cerebral ischemic damage. Free Radic Biol Med (2011) 1.05
Refined Qing Kai Ling, traditional Chinese medicinal preparation, reduces ischemic stroke-induced infarct size and neurological deficits and increases expression of endothelial nitric oxide synthase. Biol Pharm Bull (2008) 0.99
Simvastatin attenuates stroke-induced splenic atrophy and lung susceptibility to spontaneous bacterial infection in mice. Stroke (2013) 0.99
Possible lowest-energy geometry of silicon clusters Si21 and Si25. J Am Chem Soc (2003) 0.97
Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen-activated protein kinase phosphatase-1. J Leukoc Biol (2013) 0.94
Development of an ELISA-array for simultaneous detection of five encephalitis viruses. Virol J (2012) 0.86
Herpes simplex virus type 2 triggers reactivation of Kaposi's sarcoma-associated herpesvirus from latency and collaborates with HIV-1 Tat. PLoS One (2012) 0.86
Brain microvascular endothelial cells mediate neuroprotective effects on ischemia/reperfusion neurons. J Ethnopharmacol (2010) 0.84
Exploration of the mechanism for LPFFD inhibiting the formation of beta-sheet conformation of A beta(1-42) in water. J Mol Model (2010) 0.84
Molecular dynamics simulation of melting and crystallization processes of polyethylene clusters confined in armchair single-walled carbon nanotubes. J Mol Model (2015) 0.82
MoGrr1, a novel F-box protein, is involved in conidiogenesis and cell wall integrity and is critical for the full virulence of Magnaporthe oryzae. Appl Microbiol Biotechnol (2015) 0.79
Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation. J Mol Model (2010) 0.78
Early biomarkers for post-stroke cognitive impairment. J Neurol (2012) 0.77
Function of CD147 in atherosclerosis and atherothrombosis. J Cardiovasc Transl Res (2015) 0.77
Exploration of the binding of benzimidazole-biphenyl derivatives to hemoglobin using docking and molecular dynamics simulation. Int J Biol Macromol (2010) 0.77
Vesical vs. extra-vesical patterns of recurrence after the treatment of urothelial upper tract tumors. Urol Oncol (2007) 0.76
Esculentoside A suppresses Aβ(1-42)-induced neuroinflammation by down-regulating MAPKs pathways in vivo. Neurol Res (2015) 0.76
A highly active catalytic system for Suzuki-Miyaura cross-coupling reactions of aryl and heteroaryl chlorides in water. Org Biomol Chem (2012) 0.76
Molecular dynamic simulations reveal the mechanism of binding between xanthine inhibitors and DPP-4. J Mol Model (2014) 0.76
Computational studies of the binding mechanisms of fullerenes to human serum albumin. J Mol Model (2015) 0.75
Cryopreservation and replantation of amputated rat hind limbs. Eur J Med Res (2014) 0.75
Design of switchable wettability sensor for paraquat based on clicking calix[4]arene. Org Biomol Chem (2012) 0.75
Double-pulse 1.57 μm integrated path differential absorption lidar ground validation for atmospheric carbon dioxide measurement. Appl Opt (2017) 0.75
Exploration of the binding of curcumin analogues to human P450 2C9 based on docking and molecular dynamics simulation. J Mol Model (2011) 0.75
Dynamics of heavy metals and phosphorus in the pore water of estuarine sediments following agricultural intensification in Chao Lake Valley. Environ Sci Pollut Res Int (2014) 0.75
Exploration of structure, potential energy surface, and stability of planar C3B3. J Mol Model (2009) 0.75
On the electronic structure of the low lying electronic states of vanadium trioxide. J Chem Phys (2013) 0.75
Correction to Ametoctradin is a Potent Qo Site Inhibitor of the Mitochondrial Respiration Complex III. J Agric Food Chem (2015) 0.75
Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation. J Mol Model (2009) 0.75
An insight into the structures, stabilities, and bond character of B(n)Pt (n=1∼6) clusters. J Mol Model (2014) 0.75
The Diagnostic Value of 3-Dimensional Sampling Perfection With Application Optimized Contrasts Using Different Flip Angle Evolutions (SPACE) MRI in Evaluating Lower Extremity Deep Venous Thrombus. Invest Radiol (2017) 0.75
[Modeling of the SARS coronavirus main proteinase and conformational flexibility of the active site]. Beijing Da Xue Xue Bao (2003) 0.75
Injection seeded single-frequency pulsed Nd:YAG laser resonated by an intracavity phase modulator. Appl Opt (2014) 0.75
Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5. J Mol Model (2013) 0.75
Nd:YAG ceramic laser obtained high slope-efficiency of 62% in high power applications. Opt Express (2005) 0.75
Exploration of the origin of large first hyperpolarizabilities of trisaza-bridged (36) fulleroids. J Mol Model (2010) 0.75
Stripping voltammetric analysis of organophosphate pesticides using Ni/Al layered double hydroxides as solid-phase extraction. Biosens Bioelectron (2009) 0.75
PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention. Curr Med Chem (2016) 0.75
Copper(ii)-catalyzed C5 and C7 halogenation of quinolines using sodium halides under mild conditions. Org Biomol Chem (2016) 0.75
Full-dimensional quantum dynamics of vibrationally mediated photodissociation of NH3 and ND3 on coupled ab initio potential energy surfaces: absorption spectra and NH2(Ã(2)A1)/NH2(X̃(2)B1) branching ratios. J Phys Chem A (2014) 0.75
Search for structures, potential energy surfaces, and stabilities of planar BnP(n = 1 ∼ 7). J Mol Model (2010) 0.75